• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Redhill Biopharma Ltd. (Amendment)

    1/27/22 4:31:56 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDHL alert in real time by email
    SC 13G/A 1 tm224610d6_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    RedHill Biopharma Ltd.

    (Name of Issuer)

     

    Ordinary Shares, NIS 0.01 par value per share

    (Title of Class of Securities)

     

    M8208M118

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. M8208M118

     

    1. Names of Reporting Persons
       
      Ibex Investors LLC
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
      (b) ¨
       
    3. SEC Use Only
       
    4. Citizenship or Place of Organization
       
      Colorado, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:

    5.

    SOLE VOTING POWER

     

    1,310,940*  

    6.

    SHARED VOTING POWER

     

    0  

    7.

    SOLE DISPOSITIVE POWER

     

    1,310,940*  
    8. SHARED DISPOSITIVE POWER 0  

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person
       
      1,310,940*
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
    11. Percent of Class Represented by Amount in Row (9)
       
     

    0.3%*

       
    12. Type of Reporting Person (See Instructions)
       
      OO

     

     

     

    * The Reporting Persons beneficially own 131,094 American Depository Shares representing 1,310,940 Ordinary Shares. Ownership information is as of the close of business on January 26, 2022, the business day before the date of filing of this Schedule 13G.

     

    Page 2 of 11 Pages

     

     

    CUSIP No. M8208M118

     

    1. Names of Reporting Persons
       
     

    Justin B. Borus

       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
      (b) ¨
       
    3. SEC Use Only
       
    4. Citizenship or Place of Organization
       
      USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:

    5.

    SOLE VOTING POWER

     

    1,310,940*  

    6.

    SHARED VOTING POWER

     

    0  

    7.

    SOLE DISPOSITIVE POWER

     

    1,310,940*  
    8. SHARED DISPOSITIVE POWER 0  

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person
       
      1,310,940*
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
    11. Percent of Class Represented by Amount in Row (9)
       
     

    0.3%*

       
    12. Type of Reporting Person (See Instructions)
       
     

    IN

     

     

     

    * The Reporting Persons beneficially own 131,094 American Depository Shares representing 1,310,940 Ordinary Shares. Ownership information is as of the close of business on January 26, 2022, the business day before the date of filing of this Schedule 13G.

     

    Page 3 of 11 Pages

     

     

    CUSIP No. M8208M118

     

    1. Names of Reporting Persons
       
     

    Ibex Israel Fund LLLP

       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
      (b) ¨
       
    3. SEC Use Only
       
    4. Citizenship or Place of Organization
       
     

    Delaware, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:

    5.

    SOLE VOTING POWER

     

    1,310,940*  

    6.

    SHARED VOTING POWER

     

    0  

    7.

    SOLE DISPOSITIVE POWER

     

    1,310,940*  
    8. SHARED DISPOSITIVE POWER 0  

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person
       
      1,310,940*
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
    11. Percent of Class Represented by Amount in Row (9)
       
     

    0.3%*

       
    12. Type of Reporting Person (See Instructions)
       
     

    PN

     

     

     

    * The Reporting Persons beneficially own 131,094 American Depository Shares representing 1,310,940 Ordinary Shares. Ownership information is as of the close of business on January 26, 2022, the business day before the date of filing of this Schedule 13G.

     

    Page 4 of 11 Pages

     

     

    CUSIP No. M8208M118

     

    1. Names of Reporting Persons
       
     

    Ibex GP LLC

       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
      (b) ¨
       
    3. SEC Use Only
       
    4. Citizenship or Place of Organization
       
     

    Colorado, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:

    5.

    SOLE VOTING POWER

     

    1,310,940*  

    6.

    SHARED VOTING POWER

     

    0  

    7.

    SOLE DISPOSITIVE POWER

     

    1,310,940*  
    8. SHARED DISPOSITIVE POWER 0  

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person
       
      1,310,940*
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
    11. Percent of Class Represented by Amount in Row (9)
       
     

    0.3%*

       
    12. Type of Reporting Person (See Instructions)
       
     

    OO

     

     

     

    * The Reporting Persons beneficially own 131,094 American Depository Shares representing 1,310,940 Ordinary Shares. Ownership information is as of the close of business on January 26, 2022, the business day before the date of filing of this Schedule 13G.

     

    Page 5 of 11 Pages

     

     

    CUSIP No. M8208M118

     

    1. Names of Reporting Persons
       

    Ibex Investment Holdings LLC

       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
      (b) ¨
       
    3. SEC Use Only
       
    4. Citizenship or Place of Organization
       
     

    Delaware, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:

    5.

    SOLE VOTING POWER

     

    1,310,940*  

    6.

    SHARED VOTING POWER

     

    0  

    7.

    SOLE DISPOSITIVE POWER

     

    1,310,940*  
    8. SHARED DISPOSITIVE POWER 0  

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person
       
      1,310,940*
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
    11. Percent of Class Represented by Amount in Row (9)
       
     

    0.3%*

       
    12. Type of Reporting Person (See Instructions)
       
     

    OO

     

     

     

    * The Reporting Persons beneficially own 131,094 American Depository Shares representing 1,310,940 Ordinary Shares. Ownership information is as of the close of business on January 26, 2022, the business day before the date of filing of this Schedule 13G.

     

    Page 6 of 11 Pages

     

     

    CUSIP No. M8208M118

     

    1. Names of Reporting Persons
       

    Ibex Investment Holdings II LLC

       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ¨
      (b) ¨
       
    3. SEC Use Only
       
    4. Citizenship or Place of Organization
       
     

    Delaware, USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:

    5.

    SOLE VOTING POWER

     

    1,310,940*  

    6.

    SHARED VOTING POWER

     

    0  

    7.

    SOLE DISPOSITIVE POWER

     

    1,310,940*  
    8. SHARED DISPOSITIVE POWER 0  

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person
       
      1,310,940*
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
    11. Percent of Class Represented by Amount in Row (9)
       
     

    0.3%*

       
    12. Type of Reporting Person (See Instructions)
       
     

    OO

     

     

     

    * The Reporting Persons beneficially own 131,094 American Depository Shares representing 1,310,940 Ordinary Shares. Ownership information is as of the close of business on January 26, 2022, the business day before the date of filing of this Schedule 13G.

     

    Page 7 of 11 Pages

     

     

    Item 1.

     

    (a)The name of the issuer is RedHill Biopharma Ltd. (the “Issuer”).

     

    (b)The principal executive offices of the Issuer are located at 21 Ha’arba’a Street, Tel Aviv 6473921, Israel.

     

    Item 2.

     

    (a)This Schedule 13G (this “Statement” or this “Schedule 13G”) is being filed by: (1) Justin B. Borus; (2) Ibex Investors LLC, a Colorado limited liability company (the “Investment Manager”); (3) Ibex Israel Fund LLLP, a Delaware limited liability limited partnership (the “Fund”); (4) Ibex GP LLC, a Colorado limited liability company (the “General Partner”); (5) Ibex Investment Holdings LLC, a Delaware limited liability company (“IM Holdings”); and (6) Ibex Investment Holdings II LLC, a Delaware limited liability company (“GP Holdings”) (all of the foregoing, collectively, the “Reporting Persons”). The Fund is a private investment vehicle. The Fund directly beneficially owns the Ordinary Shares (as defined below) reported in this Statement. The Investment Manager is the investment manager of the Fund. IM Holdings is the sole member of the Investment Manager. The General Partner is the general partner of the Fund. GP Holdings is the sole member of the General Partner. Justin B. Borus is the manager of the Investment Manager, IM Holdings, the General Partner and GP Holdings. Justin B. Borus, the Investment Manager, IM Holdings, the General Partner and GP Holdings may be deemed to beneficially own the Ordinary Shares directly beneficially owned by the Fund. Each Reporting Person disclaims beneficial ownership with respect to any shares other than the shares directly beneficially owned by such Reporting Person.

     

    (b)The principal business office of the Reporting Persons is c/o Ibex Investors LLC, 260 N. Josephine, Suite 300, Denver, CO 80206.

     

    (c)For citizenship information see Item 4 of the cover page of each Reporting Person.

     

    (d)This Statement relates to the Ordinary Shares, NIS 0.01 par value per share (the “Ordinary Shares”).

     

    (e)The CUSIP Number of the Ordinary Shares is M8208M118. The CUSIP Number of the related ADRs is 757468103.

     

    Page 8 of 11 Pages

     

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);

    (f)¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

    (g)¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

    (k)¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                                    

     

    Item 4. Ownership.

     

    See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the end of business on January 26, 2022, the business day prior to the date of filing of this Schedule 13G.

     

    As of the end of business on the Event Date of December 31, 2021, the Reporting Persons beneficially owned 2,616,160 Ordinary Shares, representing 0.5% of all of the outstanding Ordinary Shares.

     

    The percentages of beneficial ownership contained herein are based on 524,016,034 Ordinary Shares outstanding as of November 18, 2021, based on the Issuer’s Prospectus Supplement dated November 18, 2021 filed with the SEC on November 22, 2021.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Page 9 of 11 Pages

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    (a)Not applicable.

     

    (b)Not applicable.

     

    (c)By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 10 of 11 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 27, 2022

     

    Justin B. Borus

    Ibex Investors LLC

    Ibex Israel Fund LLLP

    Ibex GP LLC

    Ibex Investment Holdings LLC

    Ibex Investment Holdings II LLC

     

    By: /s/ Justin B. Borus  
      Justin B. Borus, for himself and as the Manager of each of the Investment Manager, IM Holdings, the General Partner (for itself and on behalf of the Fund) and GP Holdings  

     

    Page 11 of 11 Pages

     

     

    Get the next $RDHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDHL

    DatePrice TargetRatingAnalyst
    9/15/2021$23.00 → $21.00Buy
    HC Wainwright & Co.
    8/31/2021$22.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RDHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

      SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

      11/14/24 12:22:08 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Redhill Biopharma Ltd.

      SC 13G - RedHill Biopharma Ltd. (0001553846) (Subject)

      2/2/24 4:10:29 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Redhill Biopharma Ltd.

      SC 13G - RedHill Biopharma Ltd. (0001553846) (Subject)

      2/1/24 10:22:43 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

      Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement, following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's counterclaims -- Latest Court victory demonstrates RedHill's commitment to collection of the court-mandated award, upon which 9% interest continues to be accruable RALEIGH, N.C. and TEL-AVIV, Israel, May 13, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it had won its attachment petition to the Court in South Ko

      5/13/25 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

      RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes -- The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting -- H. pylori is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer[1] and a major risk factor for peptic ulcer disease[2]. With almost half the global population infected by H. pylori[3], its treatment re

      5/2/25 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

      Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants This patent grant enhances RedHill's strategic positioning in the global COVID-19 therapeutic space, a market still expected to be worth more than $3 billion in 2025[1], and expands its patent footprint in Asia, a key pharmaceutical market  RHB-107 successfully met the primary endpoint of safety and tolerability, delivering promising reduction in hospitalization efficacy results in a U.S. Phase 2 COVID-19 study[2]. Additional

      4/28/25 7:03:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Leadership Updates

    Live Leadership Updates

    See more
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Financials

    Live finance-specific insights

    See more
    • RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

      Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants i

      6/23/22 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

      TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022. The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022. The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/ev

      6/17/22 8:30:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

      TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "In 2021, RedHill's team delivered record revenues against a pandemic backdrop, overall contribution of commercial operations to the company was positive for the first time in Q4/21 and positive late-stage clinical data for two novel oral COVID-19 drugs. A very strong fourth quarter for both Talicia® and Movantik®, coupled with disciplined c

      3/17/22 7:59:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    SEC Filings

    See more
    • SEC Form 6-K filed by Redhill Biopharma Ltd.

      6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

      5/27/25 7:00:35 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Redhill Biopharma Ltd.

      6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

      5/19/25 4:05:05 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Redhill Biopharma Ltd.

      6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

      5/13/25 7:04:56 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Redhill Biopharma with a new price target

      HC Wainwright & Co. reiterated coverage of Redhill Biopharma with a rating of Buy and set a new price target of $21.00 from $23.00 previously

      9/15/21 6:06:43 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Redhill Biopharma with a new price target

      Cantor Fitzgerald initiated coverage of Redhill Biopharma with a rating of Overweight and set a new price target of $22.00

      8/31/21 6:48:45 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redhill Biopharma downgraded by WBB Securities with a new price target

      WBB Securities downgraded Redhill Biopharma from Strong Buy to Buy and set a new price target of $16.00 from $17.00 previously

      5/28/21 7:52:50 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care